Thibaut Belveyre1, Philippe Guerci1,2, Elise Pape3,2, Nathalie Thilly4,2, Kossar Hosseini4,2, Laurent Brunaud5,2, Nicolas Gambier3,2, Claude Meistelman1, Marie-Reine Losser1,2, Julien Birckener1, Julien Scala-Bertola3,2, Emmanuel Novy6. 1. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Nancy, Vandoeuvre-Lès-Nancy F-54511, France. 2. University of Lorraine, F-54000 Nancy, France. 3. Department of Clinical Pharmacology and Toxicology, University Hospital of Nancy, Vandoeuvre-Lès-Nancy F-54511, France. 4. Plateforme d'aide à la recherche Clinique, University Hospital of Nancy, Vandoeuvre-Lès-Nancy F-54511, France. 5. Department of Surgery, Endocrine and metabolic surgery, Multidisciplinary unit for obesity surgery, University Hospital of Nancy, and INSERM U1256, Vandoeuvre-Lès-Nancy F-54511, France. 6. Department of Anesthesiology and Intensive Care Medicine, University Hospital of Nancy, Vandoeuvre-Lès-Nancy F-54511, France e.novy@chru-nancy.fr.
Abstract
BACKGROUND: The optimal dose of cefoxitin for antibiotic prophylaxis in obese patients remains uncertain. We evaluated the adequacy of a 4-gram dosing regimen of cefoxitin against the most frequent pathogens that infect patients undergoing bariatric surgery. METHODS: This observational prospective study included obese patients who required bariatric surgery and a 4-gram dose of cefoxitin as an antibiotic prophylaxis. Serum concentrations were measured during surgery (incision, wound closure and in case of reinjection). The pharmacokinetic/pharmacodynamic (PK/PD) target was to obtain free cefoxitin concentrations above 4× MIC, from incision to wound closure (100% ƒT>4xMIC). The targeted MIC was based on the worst-case scenario (the highest ECOFF value of Staphylococcus aureus, Enterobacteriaceae and anaerobic bacteria). The secondary outcomes were the factors related to underdosage. RESULTS: Two hundred patients were included. The mean age of the patients was 46 (±12) years-old, and the mean BMI was 45.8 (±6.9) kg/m2 Bypass surgery was the preferred technique (84%). The percentages of patients who met the PK/PD target (100% fT>4xMIC) of cefoxitin were 37.3%, 1.1% and 0% for S. aureus, Enterobacteriaceae and anaerobic bacteria, respectively. BMIs below 50 kg/m2 (OR 0.29, 95% CI [0.11-0.75], P = 0.0107) and a shorter duration of surgery (OR 0.97, 95% CI [0.95-0.99], P = 0.004) were associated with reaching the target concentrations. CONCLUSIONS: In obese patients undergoing bariatric surgery, a regimen of 4 grams of cefoxitin led to an inadequate coverage for most common pathogens. A longer surgery duration and BMI over 50 kg/m2 increase the risk of underdosage.
BACKGROUND: The optimal dose of cefoxitin for antibiotic prophylaxis in obesepatients remains uncertain. We evaluated the adequacy of a 4-gram dosing regimen of cefoxitin against the most frequent pathogens that infect patients undergoing bariatric surgery. METHODS: This observational prospective study included obesepatients who required bariatric surgery and a 4-gram dose of cefoxitin as an antibiotic prophylaxis. Serum concentrations were measured during surgery (incision, wound closure and in case of reinjection). The pharmacokinetic/pharmacodynamic (PK/PD) target was to obtain free cefoxitin concentrations above 4× MIC, from incision to wound closure (100% ƒT>4xMIC). The targeted MIC was based on the worst-case scenario (the highest ECOFF value of Staphylococcus aureus, Enterobacteriaceae and anaerobic bacteria). The secondary outcomes were the factors related to underdosage. RESULTS: Two hundred patients were included. The mean age of the patients was 46 (±12) years-old, and the mean BMI was 45.8 (±6.9) kg/m2 Bypass surgery was the preferred technique (84%). The percentages of patients who met the PK/PD target (100% fT>4xMIC) of cefoxitin were 37.3%, 1.1% and 0% for S. aureus, Enterobacteriaceae and anaerobic bacteria, respectively. BMIs below 50 kg/m2 (OR 0.29, 95% CI [0.11-0.75], P = 0.0107) and a shorter duration of surgery (OR 0.97, 95% CI [0.95-0.99], P = 0.004) were associated with reaching the target concentrations. CONCLUSIONS: In obesepatients undergoing bariatric surgery, a regimen of 4 grams of cefoxitin led to an inadequate coverage for most common pathogens. A longer surgery duration and BMI over 50 kg/m2 increase the risk of underdosage.
Authors: Teena Chopra; Dror Marchaim; Ylinne Lynch; Chris Kosmidis; Jing J Zhao; Sorabh Dhar; Naasha Gheyara; Deborah Turner; Don Gulish; Michael Wood; George Alangaden; Keith S Kaye Journal: Am J Infect Control Date: 2012-02-10 Impact factor: 2.918
Authors: Pierre Moine; Scott W Mueller; Jonathan A Schoen; Kevin B Rothchild; Douglas N Fish Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Konstantinos Z Vardakas; Georgios D Kalimeris; Nikolaos A Triarides; Matthew E Falagas Journal: Expert Opin Drug Saf Date: 2018-04-18 Impact factor: 4.250